ERα, SKP2 and E2F-1 form a feed forward loop driving late ERα targets and G1 cell cycle progression

Oncogene

Volumn 33, Issue 18, 2014, Pages 2341-2353

  Zhou, W ^a,b   Srinivasan, S ^a,b   Nawaz, Z ^a,b   Slingerland, J M ^a,b  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Coactivator; Cyclin E CDK2; E2F 1; ER ; Ubiquitylation

Indexed keywords

BLOOM SYNDROME HELICASE; CYCLIN DEPENDENT KINASE 2; CYCLIN E; ESTROGEN RECEPTOR ALPHA; RNA POLYMERASE II; S PHASE KINASE ASSOCIATED PROTEIN 2; STEROID RECEPTOR COACTIVATOR 3; TRANSCRIPTION FACTOR E2F1;

ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; TRANSACTIVATION; TUMOR GENE; UBIQUITINATION; UPREGULATION;

CYCLIN E; CYCLIN-DEPENDENT KINASE 2; E2F1 TRANSCRIPTION FACTOR; ESTROGEN RECEPTOR ALPHA; G1 PHASE CELL CYCLE CHECKPOINTS; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HUMANS; MCF-7 CELLS; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; RECQ HELICASES; RNA POLYMERASE II; S-PHASE KINASE-ASSOCIATED PROTEINS; TRANSCRIPTIONAL ACTIVATION;

EID: 84899955120     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.197     Document Type: Article

References (62)

1. Migliaccio A, DiDomenico M, Castona C, DeFalco A, Bontempo P, Nola E et al. Tyrosine kinas/p21ras/MAP-kinase pathway activation by estradiol receptor complex in MCF-7 cells. EMBO J 1996; 15: 1292-1300.
2. Nilsson S, Gustafsson JA. Estrogen receptor transcription and transactivation: basic aspects of estrogen action. Breast Cancer Res 2000; 2: 360-366.
3. Klinge CM. Estrogen receptor interaction with co-activators and co-repressors. Steroids 2000; 65: 227-251.
4. Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, Slingerland JM. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci USA 2000; 97: 9042-9046.
5. Danielian PS, White R, Lees JA, Parker MG. Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J 1992; 11: 1025-1033.
6. Alarid ET, Bakopoulos N, Solodin N. Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. Mol Endocrinol 1999; 13: 1522-1534.
7. Nawaz Z, Lonard DM, Dennis AP, Smith CL, O'Malley BW. Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci USA 1999; 96: 1858-1862.
8. Dace A, Zhao L, Park KS, Furuno T, Takamura N, Nakanishi M et al. Hormone binding induces rapid proteasome-mediated degradation of thyroid hormone receptors. Proc Natl Acad Sci USA 2000; 97: 8985-8990.
9. Shen T, Horwitz KB, Lange CA. Transcriptional hyperactivity of human progesterone receptors is coupled to their ligand-dependent down-regulation by mitogen-activated protein kinase dependent phosphorylation of serine 294. Mol Cell Biol 2001; 21: 6122-6131.
10. Lonard DM, Nawaz Z, Smith CL, O'Malley BW. The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen reeptor-alpha transactivation. Mol Cell 2000; 5: 939-948.
11. Reid G, Hubner MR, Metivier R, Brand H, Denger S, Manu D et al. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell 2003; 11: 695-707.
12. Alarid ET, Preisler-Mashek MT, Solodin NM. Thyroid hormone is an inhibitor of estrogen-induced degradation of estrogen receptor-alpha protein: estrogendependent proteolysis is not essential for receptor transactivation function in the pituitary. Endocrinology 2003; 144: 3469-3476.
13. Fan M, Nakshatri H, Nephew KP. Inhibiting proteasomal proteolysis sustains estrogen receptoralpha activation. Mol Endocrinol 2004; 18: 2603-2615.
14. Tansey WP. Transcriptional activation: risky business. Genes Dev 2001; 15: 1045-1050.
15. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002; 82: 373-428.
16. Nawaz Z, Lonard DM, Smith CL, Lev-Lehman E, Tsai SY, Tsai MJ et al. The Angelman syndromeassociated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily. Mol Cell Biol 1999; 19: 1182-1189.
17. Saji S, Okumura N, Eguchi H, Nakashima S, Suzuki A, Toi M et al. MDM2 enhances the function of estrogen receptor alpha in human breast cancer cells. Biochem Biophys Res Commun 2001; 281: 259-265.
18. Cenciarelli C, Chiaur DS, Guardavaccaro D, Parks W, Vidal M, Pagano M. Identification of a human family of F-box proteins. Curr Biol 1999; 9: 1177-1179.
19. Nigg EA. Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle. BioEssays 1995; 17: 471-480.
20. Woo RA, Poon RY. Cyclin-dependent kinases and S phase control in mammalian cells. cc 2003; 2: 316-324.
21. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999; 1: 193-199.
22. Schulman BA, Carrano AC, Jeffrey PD, Bowen Z, Kinnucan ER, Finnin MS et al. Insights into SCF ubiquitin ligases from the structure of the Skp1-Skp2 complex. Nature 2000; 408: 381-386.
23. Hao B, Zheng N, Schulman BA, Wu G, Miller JJ, Pagano M et al. Structural basis of the Cks1-dependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase. Mol Cell 2005; 20: 9-19.
24. Bhatt S, Xiao Z, Meng Z, Katzenellenbogen BS. Phosphorylation by p38 mitogenactivated protein kinase promotes estrogen receptor alpha turnover and functional activity via the SCFSKP2 proteasomal complex. Mol Cell Biol 2012; 32: 1928-1943.
25. Sun J, Zhou W, Kaliappan K, Nawaz Z, Slingerland JM. ERa phosphorylation at Y537 by Src triggers E6-AP-ERaBinding, ERa ubiquitylation, promoter occupancy, and target gene expression. Mol Endocrinol 2012; 26: 1567-1577.
26. Gu Y, Rosenblatt J, Morgan DO. Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J 1992; 11: 3995-4005.
27. Wirbelauer C, Sutterluty H, Blondel M, Gstaiger M, Peter M, Reymond F et al. The F-box protein Skp2 is a ubiquitylation target of a Cul1-based core ubiquitin ligase complex: evidence for a role of Cul1 in the suppression of Skp2 expression in quiescent fibroblasts. EMBO J 2000; 19: 5362-5375.
28. Chu I, Arnaout A, Loiseau S, Sun J, Seth A, McMahon C et al. Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer. J Clin Invest 2007; 117: 2205-2215.
29. Lin CY, Vega VB, Thomsen JS, Zhang T, Kong SL, Xie M et al. Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet 2007; 3: e87.
30. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J et al. Genome-wide analysis of estrogen receptor binding sites. Nat Genet 2006; 38: 1289-1297.
31. Lin Z, Reierstad S, Huang CC, Bulun SE. Novel estrogen receptor-A binding sites and estradiol target genes identified by chromatin immunoprecipitation cloning in breast cancer. Cancer Res 2007; 67: 5017-5024.
32. Kennedy BA, Gao W, Huang TH, Jin VX. HRTBLDb: an informative data resource for hormone receptors target binding loci. Nucleic Acids Res 2010; 38: Database issue D676-D681.
33. Iso T, Futami K, Iwamoto T, Furuichi Y. Modulation of the expression of bloom helicase by estrogenic agents. Biol Pharm Bull 2007; 30: 266-271.
34. Wang W, Dong L, Saville B, Safe S. Transcriptional activation of E2F1 gene expression by 17betaestradiol in MCF-7 cells is regulated by NF-Y-Sp1/estrogen receptor interactions. Mol Endocrinol 1999; 13: 1373-1387.
35. Nawaz Z, O'Malley BW. Urban renewal in the nucleus: is protein turnover by proteasomes absolutely required for nuclear receptor-regulated transcription? Mol Endocrinol 2004; 18: 493-499.
36. Fan S, Wang J, Yuan R, Ma Y, Meng Q, Erdos MR et al. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 1999; 284: 1354-1356.
37. Ohtake F, Takeyama K, Matsumoto T, Kitagawa H, Yamamoto Y, Nohara K et al. Modulation of oestrogen receptor signalling by association with the activated dioxin receptor. Nature 2003; 423: 545-550.
38. Johnson AE, Le IP, Buchwalter A, Burnatowska-Hledin MA. Estrogen-dependent growth and estrogen receptor (ER)-alpha concentration in T47D breast cancer cells are inhibited by VACM-1, a cul 5 gene. Mol Cell Biochem 2007; 301: 13-20.
39. Yu ZK, Gervais JL, Zhang H. Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins. Proc Natl Acad Sci USA 1998; 95: 11324-11329.
40. Nakayama K, Nagahama H, Minamishima YA, Matsumoto M, Nakamichi I, Kitagawa K et al. Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication. EMBO J 2000; 19: 2069-2081.
41. Li X, Zhao Q, Liao R, Sun P, Wu X. The SCF(Skp2) ubiquitin ligase complex interacts with the human replication licensing factor Cdt1 and regulates Cdt1 degradation. J Biol Chem 2003; 278: 30854-30858.
42. Moro L, Arbini AA, Marra E, Greco M. Up-regulation of Skp2 after prostate cancer cell adhesion to basement membranes results in BRCA2 degradation and cell proliferation. J Biol Chem 2006; 281: 22100-22107.
43. Wu J, Zhang X, Zhang L, Wu CY, Rezaeian AH, Chan CH et al. Skp2 E3 ligase integrates ATM activation and homologous recombination repair by ubiquitinating NBS1. Mol Cell 2012; 46: 351-361.
44. Berthet C, Aleem E, Coppola V, Tessarollo L, Kaldis P. Cdk2 knockout mice are viable. Curr Biol 2003; 13: 1775-1785.
45. Pagano M, Pepperkok R, Ludas J, Baldin V, Ansorge W, Bartek J et al. Regultion of the human cell cycle by the Cdk2 protein kinase. J Cell Biol 1993; 121: 101-111.
46. Tsai LH, Lees E, Faha B, Harlow E, Riabowol K. The cdk2 kinase is required for the G1-to-S transition in mammalian cells. Oncogene 1993; 8: 1593-1602.
47. Chi Y, Welcker M, Hizli AA, Posakony JJ, Aebersold R, Clurman BE. Identification of CDK2 substrates in human cell lysates. Genome Biol 2008; 9: R149.
48. Harper JW, Adams PD. Cyclin-dependent kinases. Chem Rev 2001; 101: 2511-2526.
49. Dyson N. The regulation of E2F by pRB-family proteins. Genes Develop 1998; 12: 2245-2262.
50. Zhang L, Wang C. F-box protein Skp2: a novel transcriptional target of E2F. Oncogene 2005; 25: 2615-2627.
51. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008; 8: 253-267.
52. Marti A, Wirbelauer C, Scheffner M, Krek W. Interaction between ubiquitin-protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation. Nat Cell Biol 1999; 1: 14-19.
53. Won KA, Reed SI. Activation of cyclin E/CDK2 is coupled to site-specific utophosphorylation and ubiquitin-dependent degradation of cyclin. EMBO J 1996; 15: 4182-4193.
54. Atsriku C, Britton DJ, Held JM, Schilling B, Scott GK, Gibson BW et al. Systematic mapping of posttranslational modifications in human estrogen receptor-A with emphasis on novel phosphorylation sites. Mol Cell Proteomics 2009; 8: 467-480.
55. Held JM, Britton DJ, Scott GK, Lee EL, Schilling B, Baldwin MA et al. Ligand binding promotes CDK-dependent phosphorylation of ER-alpha on hinge serine 294 but inhibits ligand 30 independent phosphorylation of serine 305. Mol Cancer Res 2012; 10: 1120-1132.
56. Dubik D, Dembinski TC, Shiu RP. Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Res 1987; 47(24.Pt.1): 6517-6521.
57. Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 2001; 29: 2905-2919.
58. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000; 60: 3689-3695.
59. Chu I, Sun J, Arnaout A, Kahn H, Hanna W, Narod S et al. p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell 2007; 128: 281-294.
60. Daly RJ, Darbre PD. Cellular and molecular events in loss of estrogen sensitivity in ZR-75-1 and T-47-D human breast cancer cells. Cancer Res 1990; 50: 5868-5875.
61. Kraus WL, Kadonaga JT. p300 and estrogen receptor cooperatively activate transcription via differential enhancement of initiation and reinitiation. Genes Dev 1998; 12: 331-342.
62. Sun J, Nawaz Z, Slingerland JM. Long-range activation of GREB1 by estrogen receptor via three distal consensus estrogen responsive elements in breast cancer cells. Mol Endocrinol 2007; 21: 2651-2662.